Microbial proteins, enzymes, and nucleic acids

Microbial proteins, enzymes, and nucleic acids represent the collective molecular machinery of infectious agents that are exploited for therapeutic intervention. This category includes high-value targets such as bacterial cell wall synthesis enzymes (e.g., transpeptidases), protein synthesis apparatus (e.g., the 30S and 50S ribosomal subunits), and nucleic acid replication enzymes (e.g., DNA gyrase and RNA polymerases) (StatPearls, 2023; NIH, 2022). The therapeutic strategy relies on selective toxicity, where drugs bind to microbial variants of these molecules that are either absent in humans or sufficiently divergent to allow for specific inhibition (IUPHAR/BPS Guide to Pharmacology). Despite the success of drugs like penicillins, macrolides, and fluoroquinolones, the field faces a perpetual challenge from antimicrobial resistance (AMR), driven by target site mutations and enzymatic degradation of drugs (WHO, 2023). Consequently, drug discovery efforts continue to seek novel microbial targets and resistance-proof inhibitors to maintain clinical efficacy against evolving pathogens (PubMed, 2021).

Other names

Microbial molecular targetsPathogen-derived targetsAntimicrobial targetsBacterial and viral components

Antimicrobial agents target these microbial components to inhibit essential life processes such as cell wall assembly, protein translation, and nucleic acid replication, often through competitive or non-competitive inhibition of specific enzymes or structural proteins.